TABLE 1.
Patient no. (HIV-1 disease status) | Clone | TCR α/β | CD2 | CD3 | CD14 | CD20 | Cytokine (U/ml)
|
|
---|---|---|---|---|---|---|---|---|
IFN-γ | IL-4 | |||||||
1 (NPb) | NP1-1 | + | + | + | − | − | 246 | 0 |
NP1-2 | + | + | + | − | − | 194 | 0 | |
NP1-3 | + | + | + | − | − | 258 | 0 | |
NP1-4 | + | + | + | − | − | 208 | 0 | |
NP1-5 | + | + | + | − | − | 188 | 0 | |
NP1-6 | + | + | + | − | − | 144 | 0 | |
NP1-7 | + | + | + | − | − | 267 | 0 | |
2 (NP) | NP2-1 | + | + | + | − | − | 75 | 0 |
NP2-4 | + | + | + | − | − | 108 | 0 | |
NP2-5 | + | + | + | − | − | 88 | 0 | |
3 (AIDS) | AD1-1 | + | + | + | − | − | 44 | 0 |
AD1-3 | + | + | + | − | − | 66 | 0 | |
AD1-6 | + | + | + | − | − | 248 | 0 | |
AD1-8 | + | + | + | − | − | 113 | 0 | |
AD1-12 | + | + | + | − | − | 23 | 0 | |
AD1-13 | + | + | + | − | − | 131 | 0 | |
AD1-15 | + | + | + | − | − | 70 | 0 | |
AD1-18 | + | + | + | − | − | 42 | 0 | |
AD1-19 | + | + | + | − | − | 41 | 0 | |
AD1-23 | + | + | + | − | − | 70 | 0 | |
AD1-30 | + | + | + | − | − | 218 | 0 | |
4 (AIDS) | AD2-1 | + | + | + | − | − | 196 | 0 |
AD2-2 | + | + | + | − | − | 210 | 0 | |
AD2-4 | + | + | + | − | − | 76 | 0 | |
AD2-8 | + | + | + | − | − | 121 | 0 | |
None | MHCD4 | + | + | + | − | − | 131 | 0 |
None | CHCD4 | + | + | + | − | − | 117 | 0 |
Phenotypes were obtained by fluorescence-activated cell sorter analyses with appropriate negative and positive controls and by ELISA (for cytokines) as described previously (25).
NP, nonprogressor.